Related Experiment Video
Updated: Sep 13, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Patient Preferences for Self-Injectable Preventive Treatment for Migraine: A Multi-country Discrete Choice Experiment
Jaein Seo1, Caitlin Thomas2, Tommi Tervonen2
1PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA, USA. jaein.seo@thermofisher.com.
Migraine patients preferred self-injectable calcitonin gene-related peptide monoclonal antibody (CGRP mAb) autoinjectors over oral medications. Key preferences included shorter injection duration and auto-retractable needle removal for CGRP mAb devices.
Area of Science:
- Neurology
- Pharmacology
- Patient-Reported Outcomes
Background:
- Current migraine prevention options include self-injectable calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) and oral CGRP antagonists.
- Understanding patient preferences for specific delivery devices is crucial for optimizing treatment adherence and efficacy.
Purpose of the Study:
- To elicit patient preferences for self-injectable CGRP mAb autoinjectors versus non-CGRP oral medication for migraine prevention.
- To determine the relative importance of various autoinjector attributes in patient treatment choices.
Main Methods:
- A discrete choice experiment (DCE) was conducted online with 1067 adults in the USA, UK, and Germany experiencing episodic or chronic migraine.
- Participants evaluated hypothetical treatment options including two CGRP mAb autoinjectors and one non-CGRP oral medication, described by seven attributes.
- Error-component logit models were used to analyze DCE data, yielding relative attribute importance (RAI) and predicted choice probabilities (PCP).
Main Results:
- Autoinjectors were preferred over non-CGRP oral medication in 86.3% of choices.
- The most critical autoinjector attributes were injection duration (RAI 37.0%), auto-retractable needle removal (RAI 30.8%), room temperature storage (RAI 15.2%), and no pinching (RAI 12.5%).
- Autoinjector profiles similar to galcanezumab showed higher likelihood of selection compared to erenumab or fremanezumab.
Conclusions:
- Migraine patients demonstrate a strong preference for self-injectable CGRP mAb autoinjectors over oral preventive medications.
- Treatment choice is significantly influenced by autoinjector design features, particularly injection duration, needle retraction mechanism, storage convenience, and ease of use (no pinching).
Related Concept Videos
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Drug Delivery: Enteral Route

